Certara to Participate in Upcoming Investor Conferences
CERT(NASDAQ:CERT) RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor conferences:
Barclays Upgrades Certara to Overweight, Raises Price Target to $14
CERTJMP Securities Reiterates Market Perform on Certarato Market Perform
CERTCertara Affirms FY2025 Adj EPS Guidance of $0.42-$0.46 vs $0.45 Est; Affirms FY2025 Sales Guidance of $415.00M-$425.00M vs $420.67M Est
CERTCertara Q1 Adj. EPS $0.14 Beats $0.11 Estimate, Sales $106.00M Beat $104.88M Estimate
CERTKeybanc Maintains Overweight on Certara, Raises Price Target to $18
CERTTop 3 Health Care Stocks You May Want To Dump This Quarter
CERTCertara Unveils $100 Million Buyback Plan In Better-Than-Expected Preliminary Earnings Report
CERTCertara reports $106M Q1 revenue, authorizes $100M buyback, and launches a new AI-driven non-animal testing tool to support biopharma innovation.
Certara Launches Non-Animal Navigator Solution To Help Drug Developers Reduce Reliance On Animal Testing
CERTCertara Has Continued To Pursue A Strategic Evaluation Of The Regulatory Services Business; Following Public Announcement Of The Internal Business Review, Has Engaged In Discussions With Several External Parties Regarding The Regulatory Services Business
CERTCertara Reports Preliminary Q1 2025 Revenue Of $106M Up From $96.7M YoY; Reiterates FY25 Guidance; Announces $100M Share Repurchase Authorization
CERTWhat Analysts Are Saying About Certara Stock
CERTWhat's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
CERTFDA introduces a new roadmap to reduce animal testing in monoclonal antibody development using AI models, organoid testing and real-world data to enhance safety and efficiency.
Baird Maintains Neutral on Certara, Raises Price Target to $13
CERTBarclays Maintains Equal-Weight on Certara, Lowers Price Target to $11
CERTBarclays Maintains Equal-Weight on Certara, Raises Price Target to $13
CERTStephens & Co. Reiterates Overweight on Certara, Maintains $17 Price Target
CERTCertara Sees FY25 Adj. EPS $0.42-$0.46 Vs $0.50 Est.; Revenue $415M-$425M Vs $421.956M Est.
CERTCertara Q4 2024 Adj. EPS $0.15 Beats $0.13 Estimate, Sales $100.361M Beat $98.395M Estimate
CERTCertara Sees Q4 Revenues Of $99.7M, compared to $88M YoY, Sees Q4 Bookings of $144.5M
CERTCertara Sees FY24 Revenue Of $384.4M Vs. Estimate Of $386.22M (Prior View: $380M-$385M), Bookings Of $445.3M, Confirms Adjusted EBITDA Within Guidance Range Of $120M-$124M
CERTCertara Sees FY24 EPS $0.41-$0.44 Vs $0.41 Est.; Revenue $380M-$385M Vs $386.5M Est.
CERTCertara Q3 Adj $0.13 Beats $0.11 Estimate, Sales $94.82M Miss $95.53M Estimate
CERTBaird Maintains Neutral on Certara, Lowers Price Target to $13
CERTExpert Ratings for Certara
CERTOver the past 3 months, 9 analysts have published their opinion on Certara (NASDAQ:CERT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Analyst Ratings for Certara
CERTCertara (NASDAQ:CERT) has observed the following analyst ratings within the last quarter:
Berenberg Initiates Coverage On Certara with Buy Rating, Announces Price Target of $23
CERT